Chinese biotech player Akeso Biopharma has made a second attempt at filing for a Hong Kong IPO after its previous application was rejected last month for failing to meet regulatory requirements.
The company's largest institutional backer is GTJA Investment Group, which has an 8.22% stake. The healthcare specialist led a RMB200 million ($28.7 million) Series B round in May 2017. This was followed...
Sequoia Capital closed its latest set of funds for deployment in India and Southeast Asia with $1.35 billion in commitments.
Ucommune, a Chinese co-working space operator that failed to get traction with an attempted New York IPO last year, has been acquired by a US-listed special purpose acquisition company (SPAC) at a valuation of $764.9 million.
Indies Capital, a Singapore-based GP focused on Indonesia, has reached a first close of $100 million for its third flagship private equity and credit fund.
EQT has submitted a revised offer to acquire New Zealand retirement village player Metlifecare at a lower valuation after facing a legal challenge over its attempt to terminate a previously agreed deal.